Blog Posts

The Biosimilars Landscape: What All Developers Need to Know

As biosimilars to treat rheumatic diseases begin get approval from the FDA, biosimilar development remains a hot topic in drug development. Sponsors estimate a 35% growth of biosimilars in their development pipelines by 2020, but face a wide variety of regional and global markets along with shifting guidelines and recommendations, stressing the need to understand this rapidly changing landscape.

Filed In

Biosimilars
Blog Posts
Clinical Trials
Consulting
Health Economics
Pharma